Clinical Trials

It’s been an eventful year for marijuana stocks, with activity led by GW Pharmaceuticals‘ (NASDAQ: GWPH) and Corbus Pharmaceuticals‘ (NASDAQ: CRBP) clinical trial data releases and Insys Therapeutics‘ (NASDAQ: INSY) approval of its first cannabinoid product, Syndros. Continue Reading Below Let’s take a look back and see what the future holds for marijuana stocks. Image […]

by

Speakers include world-renowned physicians Meeting to begin at 8:00 am ET; webcast will be available DEVON, Pa., Dec. 08, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will host its first Clinical Research Day on […]

by

Speakers include world-renowned physicians Meeting to begin at 8:00 am ET; webcast will be available /EIN News/ — DEVON, Pa., Dec. 08, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will host its first Clinical […]

by

Speakers include world-renowned physicians Meeting to begin at 8:00 am ET; webcast will be available DEVON, Pa., Dec. 08, 2016 — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will host its first Clinical Research Day on December 15, […]

by

GW Pharmaceuticals recently presented positive results from two Phase 3 clinical trials evaluating its lead cannabidiol therapeutic candidate, Epidiolex, in patients with lennox-gastaut syndrome (LGS) and Dravet syndrome (DS), two treatment-resistant epilepsy syndromes. The presentations took place during the American Epilepsy Society (AES) Annual Meeting in Houston, Texas Dec. 2-6. Epidiolex is an oral formulation of pure […]

by

Speakers include world-renowned physicians Meeting to begin at 8:00 am ET; webcast will be available DEVON, Pa., Dec. 08, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will host its first Clinical Research Day on […]

by

The NSW government has funded the world’s largest trial of medicinal cannabis that will prevent the side effects of chemotherapy. Patients who undergo chemotherapy treatment experience nausea, vomiting and for some, bouts of oesaphigitis or inflammation of the oesephagus. Chris O’Brien Lifehouse’s associate professor Peter Grimison will lead the trial. It will be in collaboration […]

by

Medical Device Investing ZYN002 CBD gel was shown to be safe and well-tolerated across range of doses tested in healthy subjects and adult epilepsy patients with focal seizuresNo impairment in cognitive performance or changes in psychological health were observedDEVON, Pa., Dec. 05, Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development […]

by

DEVON, Pa., Nov. 28, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that two posters relating to ZYN002, its patent-protected synthetic CBD gel,  have been selected for presentation at the upcoming 70th Annual Meeting of the American Epilepsy […]

by

Researchers in Canada are preparing to launch a new clinical trial that will study the effects of edible cannabis products in the treatment of epilepsy, according to a report from the Canadian Press. The study will be conducted at Toronto’s Hospital for Sick Children, where researchers intend to get into a first-of-its-kind exploration of oral […]

by

Researchers at Toronto’s Hospital for Sick Children are poised to begin a clinical trial using cannabis extracts to treat children with severe epilepsy whose seizures can’t be controlled with existing medications. The trial is believed to be the first in Canada to test an oral preparation that contains both CBD and THC, compounds in marijuana that have been shown in the lab and through […]

by